Caribou Biosciences, Inc. is a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company engaged in developing transformative therapies for patients with devastating diseases. The Company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against disease. Caribou is advancing a pipeline of off-the-shelf cell therapies from its CAR-T platform to offer broad access and rapid availability of treatments for patients with hematologic malignancies and autoimmune diseases. Its genome-editing platform, including its novel chRDNA technology, enables more precise genome editing of allogeneic cell therapies. It is advancing its pipeline of allogeneic CAR-T cell therapies with clinical development programs targeting the treatment of hematologic malignancies and autoimmune diseases.
Growing
The company is in a growing phase, with the latest annual income totaling USD 11.16M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 11.16M.
Fairly Valued
The company’s latest PE is -1.29, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 35.96M shares, decreasing 40.06% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 545.45K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.65.